B. Sharda Pharma-Chem Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 23-12-2024
- Paid Up Capital ₹ 8.45 M
as on 23-12-2024
- Company Age 32 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.52 Cr
as on 23-12-2024
- Satisfied Charges ₹ 4.11 Cr
as on 23-12-2024
- Revenue -11.58%
(FY 2021)
- Profit 7.15%
(FY 2021)
- Ebitda 10.66%
(FY 2021)
- Net Worth 4.13%
(FY 2021)
- Total Assets -11.94%
(FY 2021)
About B. Sharda Pharma-Chem
The Corporate was formerly known as Shree Balram Paper Mills Ltd.. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 8.45 M.
The company currently has active open charges totaling ₹4.52 Cr. The company has closed loans amounting to ₹4.11 Cr, as per Ministry of Corporate Affairs (MCA) records.
Priyank Kela, Jagrutiben Kela, Gautam Kela, and One other member serve as directors at the Company.
- CIN/LLPIN
U99999GJ1992PLC017078
- Company No.
017078
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
10 Feb 1992
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- LocationNa, Gujarat
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at B. Sharda Pharma-Chem?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Priyank Kela  | Director | 24-Jul-2019 | Current |
| Jagrutiben Kela | Whole-Time Director | 27-Jun-2013 | Current |
| Gautam Kela | Whole-Time Director | 01-Jun-1995 | Current |
| Mukeshbhai Kella | Whole-Time Director | 26-Aug-2006 | Current |
Financial Performance of B. Sharda Pharma-Chem.
B. Sharda Pharma-Chem Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 11.58% decrease. The company also saw a slight improvement in profitability, with a 7.15% increase in profit. The company's net worth moved up by a moderate rise of 4.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of B. Sharda Pharma-Chem?
In 2021, B. Sharda Pharma-Chem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 01 Apr 2021 | ₹1.76 Cr | Open |
Others Creation Date: 12 Apr 2016 | ₹1.38 Cr | Open |
Others Creation Date: 31 Mar 2016 | ₹1.38 Cr | Open |
How Many Employees Work at B. Sharda Pharma-Chem?
Unlock and access historical data on people associated with B. Sharda Pharma-Chem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of B. Sharda Pharma-Chem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped B. Sharda Pharma-Chem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
